drugset
drugset / Trial / NCT05894343

Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease

NCT05894343 ↗

Phase 1/2 Active not recruiting 13 enrolled MeiraGTx, LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the long-term safety of AAV-GAD delivered bilaterally to the subthalamic nuclei (STN) in participants with Parkinson's disease.

Timeline

Start
2023-05-19
Primary completion
2029-10
Completion
2029-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AAV-GAD Gene therapy (AAV / viral vector) — Other

Indications

Parkinson disease